Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of Doxil in HER2-negative relapsed or metastatic breast cancer
ChiCTR1900022568Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2017
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival. Started Mar 2017; status: recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900022568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022568.